Physician profile
Adam Fleming
NPI 1679924963
$2,379.43
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $704 · 2023: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $371.86 | 2021-2023 | Austedo Xr |
| Genzyme Corporation | $365.59 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $222.37 | 2022 | |
| Dexcom, INC. | $207.25 | 2023 | Dexcom G7 Gss (161) |
| Medtronic, INC. | $135.43 | 2022 | |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Gemtesa |
| Averitas Pharma INC. | $121.80 | 2023 | Qutenza |
| Viiv Healthcare Company | $121.49 | 2021 | |
| Idorsia Pharmaceuticals US INC | $120.39 | 2023 | Quviviq |
| Abbvie INC. | $118.44 | 2021 | |
| Neurocrine Biosciences, INC. | $104.04 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2023 | Lifevest |
| Impel Pharmaceuticals INC. | $99.99 | 2022 | |
| Inari Medical, INC. | $58.57 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $55.23 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $51.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.